Literature DB >> 9333058

Chlorproguanil-dapsone: effective treatment for uncomplicated falciparum malaria.

E Amukoye1, P A Winstanley, W M Watkins, R W Snow, J Hatcher, M Mosobo, E Ngumbao, B Lowe, M Ton, G Minyiri, K Marsh.   

Abstract

Pyrimethamine-sulfadoxine, the first choice for uncomplicated falciparum malaria in Africa, exerts strong selection pressure for resistance because of its slow elimination. It is likely that resistance will emerge rapidly, and there is no widely affordable replacement. Chlorproguanil-dapsone is cheap, rapidly eliminated, more potent than pyrimethamine-sulfadoxine, and could be introduced in the near future to delay the onset of antifolate resistance and as "salvage therapy" for pyrimethamine-sulfadoxine failure. A total of 448 children were randomly allocated (double blind) to either a single dose of pyrimethamine-sulfadoxine or to one of two chlorproguanil-dapsone regimens: a single dose or three doses at 24-h intervals. Reinfections are clinically indistinguishable from recrudescence and are more likely after treatment with rapidly eliminated drugs; we measured the incidence of parasitemia in 205 initially aparasitemic children to allow comparison with the three treatment groups. The patients and a community surveillance group were followed up for 28 days. At the study end point, 31.2% (95% confidence interval, 24.9-38.0) of the community surveillance group subjects were parasitemic, compared with subjects in the treatment groups, whose rates of parasitemia were 40.8% (32.9-49.0; relative risk [RR], 1.31 [0.99-1.73]) after triple-dose chlorproguanil-dapsone, 19.7% (13.5-27.2; RR, 0.63 [0.43-0.93]) after pyrimethamine-sulfadoxine, and 65.6% (57.5-73.0; RR, 2.10 [1.66-2.65]) after single-dose chlorproguanil-dapsone. Pyrimethamine-sulfadoxine and triple-dose chlorproguanil-dapsone were effective treatments. Pyrimethamine-sulfadoxine provided chemoprophylaxis during follow-up because of its slow elimination. Triple-dose chlorproguanil-dapsone should now be developed in an attempt to reduce the rate of emergence of antifolate resistance in Africa and for affordable salvage therapy in cases of pyrimethamine-sulfadoxine failure.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9333058      PMCID: PMC164103     

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  23 in total

1.  Treatment of Plasmodium falciparum malaria with pyrimethamine-sulfadoxine: selective pressure for resistance is a function of long elimination half-life.

Authors:  W M Watkins; M Mosobo
Journal:  Trans R Soc Trop Med Hyg       Date:  1993 Jan-Feb       Impact factor: 2.184

2.  Periodicity and space-time clustering of severe childhood malaria on the coast of Kenya.

Authors:  R W Snow; J R Schellenberg; N Peshu; D Forster; C R Newton; P A Winstanley; I Mwangi; C Waruiru; P A Warn; C Newbold
Journal:  Trans R Soc Trop Med Hyg       Date:  1993 Jul-Aug       Impact factor: 2.184

3.  The disposition of oral and intramuscular pyrimethamine/sulphadoxine in Kenyan children with high parasitaemia but clinically non-severe falciparum malaria.

Authors:  P A Winstanley; W M Watkins; C R Newton; C Nevill; E Mberu; P A Warn; C M Waruiru; I N Mwangi; D A Warrell; K Marsh
Journal:  Br J Clin Pharmacol       Date:  1992-02       Impact factor: 4.335

Review 4.  The dihydrofolate reductase-thymidylate synthetase gene in the drug resistance of malaria parasites.

Authors:  J E Hyde
Journal:  Pharmacol Ther       Date:  1990       Impact factor: 12.310

5.  Treatment of chloroquine-resistant malaria in African children: a cost-effectiveness analysis.

Authors:  P Sudre; J G Breman; D McFarland; J P Koplan
Journal:  Int J Epidemiol       Date:  1992-02       Impact factor: 7.196

6.  A single dose of intramuscular sulfadoxine-pyrimethamine as an adjunct to quinine in the treatment of severe malaria: pharmacokinetics and efficacy.

Authors:  C R Newton; P A Winstanley; W M Watkins; I N Mwangi; C M Waruiru; E K Mberu; P A Warn; C G Nevill; K Marsh
Journal:  Trans R Soc Trop Med Hyg       Date:  1993 Mar-Apr       Impact factor: 2.184

7.  Beyond chloroquine: implications of drug resistance for evaluating malaria therapy efficacy and treatment policy in Africa.

Authors:  P B Bloland; E M Lackritz; P N Kazembe; J B Were; R Steketee; C C Campbell
Journal:  J Infect Dis       Date:  1993-04       Impact factor: 5.226

8.  Primary structure and expression of the dihydropteroate synthetase gene of Plasmodium falciparum.

Authors:  T Triglia; A F Cowman
Journal:  Proc Natl Acad Sci U S A       Date:  1994-07-19       Impact factor: 11.205

9.  Sequence variation of the hydroxymethyldihydropterin pyrophosphokinase: dihydropteroate synthase gene in lines of the human malaria parasite, Plasmodium falciparum, with differing resistance to sulfadoxine.

Authors:  D R Brooks; P Wang; M Read; W M Watkins; P F Sims; J E Hyde
Journal:  Eur J Biochem       Date:  1994-09-01

10.  In vitro activities of novel antifolate drug combinations against Plasmodium falciparum and human granulocyte CFUs.

Authors:  P A Winstanley; E K Mberu; I S Szwandt; A M Breckenridge; W M Watkins
Journal:  Antimicrob Agents Chemother       Date:  1995-04       Impact factor: 5.191

View more
  13 in total

Review 1.  Pharmacokinetic interactions of antimalarial agents.

Authors:  P T Giao; P J de Vries
Journal:  Clin Pharmacokinet       Date:  2001       Impact factor: 6.447

2.  Role of Plasmodium vivax Dihydropteroate Synthase Polymorphisms in Sulfa Drug Resistance.

Authors:  Wichai Pornthanakasem; Pinpunya Riangrungroj; Penchit Chitnumsub; Wanwipa Ittarat; Darin Kongkasuriyachai; Chairat Uthaipibull; Yongyuth Yuthavong; Ubolsree Leartsakulpanich
Journal:  Antimicrob Agents Chemother       Date:  2016-07-22       Impact factor: 5.191

3.  Towards an understanding of the mechanism of pyrimethamine-sulfadoxine resistance in Plasmodium falciparum: genotyping of dihydrofolate reductase and dihydropteroate synthase of Kenyan parasites.

Authors:  A M Nzila; E K Mberu; J Sulo; H Dayo; P A Winstanley; C H Sibley; W M Watkins
Journal:  Antimicrob Agents Chemother       Date:  2000-04       Impact factor: 5.191

4.  Efficacy of amodiaquine/artesunate combination therapy for uncomplicated malaria in children under five years in ghana.

Authors:  Ka Koram; L Quaye; B Abuaku
Journal:  Ghana Med J       Date:  2008-06

5.  Characteristics of Plasmodium falciparum dhfr haplotypes that confer pyrimethamine resistance, Kilifi, Kenya, 1987--2006.

Authors:  Laura K Certain; Marnie Briceño; Steven M Kiara; Alexis M Nzila; William M Watkins; Carol Hopkins Sibley
Journal:  J Infect Dis       Date:  2008-06-15       Impact factor: 5.226

6.  Pyrimethamine and WR99210 exert opposing selection on dihydrofolate reductase from Plasmodium vivax.

Authors:  Michele D Hastings; Carol Hopkins Sibley
Journal:  Proc Natl Acad Sci U S A       Date:  2002-08-27       Impact factor: 11.205

7.  Kenyan Plasmodium falciparum field isolates: correlation between pyrimethamine and chlorcycloguanil activity in vitro and point mutations in the dihydrofolate reductase domain.

Authors:  A Nzila-Mounda; E K Mberu; C H Sibley; C V Plowe; P A Winstanley; W M Watkins
Journal:  Antimicrob Agents Chemother       Date:  1998-01       Impact factor: 5.191

8.  Randomized trial of safety and effectiveness of chlorproguanil-dapsone and lumefantrine-artemether for uncomplicated malaria in children in the Gambia.

Authors:  Samuel Dunyo; Giorgio Sirugo; Sanie Sesay; Cyrille Bisseye; Fanta Njie; Majidah Adiamoh; Davis Nwakanma; Mathurin Diatta; Ramatoulie Janha; Fatou Sisay Joof; Beth Temple; Paul Snell; David Conway; Robert Walton; Yin Bun Cheung; Paul Milligan
Journal:  PLoS One       Date:  2011-06-07       Impact factor: 3.240

9.  Changing Malaria Prevalence on the Kenyan Coast since 1974: Climate, Drugs and Vector Control.

Authors:  Robert W Snow; Eliud Kibuchi; Stella W Karuri; Gilbert Sang; Caroline W Gitonga; Charles Mwandawiro; Philip Bejon; Abdisalan M Noor
Journal:  PLoS One       Date:  2015-06-24       Impact factor: 3.240

10.  Chloroquine resistance before and after its withdrawal in Kenya.

Authors:  Leah Mwai; Edwin Ochong; Abdi Abdirahman; Steven M Kiara; Steve Ward; Gilbert Kokwaro; Philip Sasi; Kevin Marsh; Steffen Borrmann; Margaret Mackinnon; Alexis Nzila
Journal:  Malar J       Date:  2009-05-18       Impact factor: 2.979

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.